Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1569
HER2amp
Basal A
Sigma A6730
AKT
AKT
10872.153
uM
9.73860
17.79130
-0.8670 -1.0000 1.8231 0.2406
0.9913
1.5576
HCC1569
HER2amp
Basal A
Sigma A6730
AKT
AKT
12523.165
uM
8.57050
18.45990
-0.5139 -0.8139 1.2592 0.2049
0.9973
1.0249
HCC1569
HER2amp
Basal A
Sirolimus
MTOR
MTOR
7824.068
uM
1.5290
999.99450
0.1952 -0.5186 0.1098 0.4482
0.6902
1.5619
HCC1569
HER2amp
Basal A
Sirolimus
MTOR
MTOR
7827.068
uM
0.18897
2.8360
-0.0235 -0.3457 0.1940 0.5357
0.8566
1.1786
HCC1569
HER2amp
Basal A
Sirolimus
MTOR
MTOR
7447.068
uM
0.01777
0.00189
0.2985 0.3535 0.5478 0.5385
0.9617
1.5836
HCC1569
HER2amp
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7448.084
uM
377.7270
582.81760
-0.5975 -1.0000 2.5331 0.1873
0.8866
2.8225
HCC1569
HER2amp
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7449.084
uM
96.43570
56.02520
0.3520 0.4669 5.0000 0.1506
0.8883
2.1410
HCC1569
HER2amp
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7447.084
uM
49.56820
67.98270
-0.9217 -0.9241 3.3134 0.4033
0.9985
1.5152
HCC1569
HER2amp
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7449.067
uM
inf
inf
-0.7828 -0.7828 0.0000 0.2385
0.4093
1.9771
HCC1569
HER2amp
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7447.067
uM
7.05180
10.27510
-0.9623 -0.9663 2.8581 0.4142
0.9990
1.5637
HCC1569
HER2amp
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7448.067
uM
9.64030
13.36540
-0.6825 -0.6845 2.6397 0.3276
0.9997
2.8462
HCC1569
HER2amp
Basal A
Taxol
TUBB
TUBB
9347.002
uM
0.01361
0.00945
0.3664 0.4193 4.9989 0.3606
0.9845
1.4904
HCC1569
HER2amp
Basal A
Taxol
TUBB
TUBB
13038.002
uM
0.01142
0.01074
0.0639 0.1336 5.0000 0.5396
0.9898
1.2045
HCC1569
HER2amp
Basal A
TCS 2312
CHK1
CHK
10872.152
uM
0.45631
0.58592
-0.4297 -0.3973 2.3390 0.4808
0.9894
1.5916
HCC1569
HER2amp
Basal A
TCS 2312
CHK1
CHK
12523.152
uM
0.51831
0.61186
-0.7533 -0.6456 4.9967 0.4818
0.9912
0.8423
HCC1569
HER2amp
Basal A
TCS PIM-1 1
Pim kinase
PIM
12523.135
uM
inf
inf
0.8989 0.8989 0.0000 -0.0174
0.4377
0.8958
HCC1569
HER2amp
Basal A
TCS PIM-1 1
Pim kinase
PIM
10872.148
uM
inf
inf
0.7165 0.7165 0.0000 0.0270
0.4986
1.5151
HCC1569
HER2amp
Basal A
Temsirolimus
MTOR
MTOR
10872.144
uM
1.01770
19.31340
-0.8843 -1.0000 0.3733 0.4792
0.7299
1.5447
HCC1569
HER2amp
Basal A
Temsirolimus
MTOR
MTOR
12523.168
uM
1.65560
16.16170
-0.9526 -1.0000 0.4822 0.4550
0.8142
0.9035
HCC1569
HER2amp
Basal A
Topotecan
TOP1
TOP
7825.007
uM
7.49910
55.04090
-0.2342 -1.0000 0.5512 0.2742
0.9642
1.5199
HCC1569
HER2amp
Basal A
Topotecan
TOP1
TOP
9347.121
uM
0.38685
0.43297
-0.0698 -0.0755 1.2491 0.4610
0.9938
1.4523
HCC1569
HER2amp
Basal A
Torkinib
15388.211
uM
0.00154
0.18585
-0.5621 -1.0000 0.2292 0.9195
0.9903
1.5247
HCC1569
HER2amp
Basal A
Tozasertib
AURK/FLT3/ABL/JAK2
AURK
12523.169
uM
1.51170
10.62030
-0.8801 -1.0000 0.5635 0.4311
0.9141
1.0498
HCC1569
HER2amp
Basal A
Tozasertib
AURK/FLT3/ABL/JAK2
AURK
10872.15
uM
2.77970
38.01430
-0.0563 -1.0000 0.4200 0.2568
0.9220
1.6255
HCC1569
HER2amp
Basal A
TPCA-1
IKK
NFKB
10442.093
uM
3.53090
3.58680
0.0292 -0.0091 1.1506 0.2378
0.9922
1.6861